Skip to main content

Table 1 Correlation of clinicopathological data of breast cancer patients with TGIF expression levels

From: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Parameter Category Overall TGIF expression p-value
0–2 3–12
N % N % N %
All patients   1197   475 39.7% 722 60.3%  
Age (years) < 40 185 15.5% 73 15.4% 112 15.5% 0.756
  40–50 489 40.9 196 41.3% 293 40.6%  
  51–65 496 41.4% 56 48.7% 440 40.7%  
  > 65 27 2.3% 8 1.7% 19 2.6%  
Tumor stage (pT) pT1 394 33.0% 134 28.4% 260 36.1% 0.015
  pT2 665 55.7% 286 60.6% 379 52.6%  
  pT3/4 134 11.2% 52 11.0% 82 11.4%  
  total 1193   472   721   
  missing 4       
Lymph node status (pN) pN1 493 41.2% 181 38.1% 312 43.2% 0.114
  pN2 398 33.2% 159 33.5% 239 33.1%  
  pN3 306 25.6% 135 28.4% 171 23.7%  
Tumor grading (G) G1 39 3.3% 13 2.7% 26 3.6% < 0.001
  G2 588 49.2% 196 41.4% 392 54.3%  
  G3 569 47.6% 265 55.9% 304 42.1%  
  missing 1       
Histological type ductal 930 77.7% 389 81.9% 541 74.9% 0.009
  lobular 136 11.4% 39 8.2% 97 13.4%  
  others 131 10.9% 47 9.9% 84 11.6%  
HER2 positive 248 22.0% 89 20.4% 159 23.0% 0.303
  negative 880 78.0% 348 79.6% 532 77.0%  
  missing 69       
ER positive 886 74.0% 322 67.8% 564 78.1% < 0.001
  negative 311 26.0% 153 32.2% 158 21.9%  
PR positive 819 68.4% 285 60.0% 534 74.0% < 0.001
  negative 378 31.6% 190 40.0% 188 26.0%  
Treatment in mITTset iddEPC 597 49.9% 232 48.8% 365 50.6% 0.595
  ddEC-PwX 600 50.1% 243 51.2% 357 49.4%  
Ibandronate treatment with Ibandronate 781 65.2% 307 64.6% 474 65.7% 0.756
  without Ibandronate 416 34.8% 168 35.4% 248 34.3%  
  1. Data are N (valid %) unless otherwise state
  2. mITT modified intention-to treat, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, iddEPC intense dose-dense epirubicin plus paclitaxel plus cyclophosphamide, ddEC-PwX dose-dense epirubicin plus cyclophosphamide plus paclitaxel weekly and capecitabine